Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

NCT06569420 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

275

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
ALK-positive
SAF-189s

Interventions

OTHER: Drug: Foritinib Succinate
OTHER: Drug: Crizotinib

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.